Activity Info

This activity examines emerging therapies for Duchenne muscular dystrophy (DMD), focusing on the role of abnormal HDAC activity in disease progression and its effects on inflammation, muscle loss, fat formation, and fibrosis. Our expert faculty reviews recent clinical and real-world data, explores how new treatments fit into existing regimens, and uses case scenarios to demonstrate integration into polypharmacy strategies.